During the past years, growing evidence of a pronounced antidepressant effect of quetiapine has been demonstrated in several studies
Conditions
Interventions
Trade Name: Seroquel Prolong
Pharmaceutical Form: Buccal tablet
Trade Name: Remergil SolTab
Pharmaceutical Form: Soluble tablet
Sponsors
Technical University Munich, Klinikum rechts der Isar
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: For inclusion in the study patients must fulfil all of the following criteria: 1. Provision of written informed consent 2. A diagnosis of Major depressive disorder by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, revised (DSM-IV-R) 3. Females and males aged 18 to 65 years 4. Female patients of childbearing potential must be using a reliable method of contraception and have a negative urine human chorionic gonadotropin (HCG) test at enrolment 5. Able to understand and comply with the requirements of the study 6. Minimum score in the HAMD-21 scale: 18 Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Any of the following is regarded as a criterion for exclusion from the study: 1. Pregnancy or lactation 2. Any DSM-IV-R Axis I disorder not defined in the inclusion criteria 3. Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others 4. Known intolerance or lack of response to quetiapine fumarate and / or mirtazapine, as judged by the investigator 5. Use of any of the following cytochrome P450 3A4 inhibitors in the 14 days preceding enrolment including but not limited to: ketoconazole, itraconazole, fluconazole, erythromycin, clarithromycin, troleandomycin, indinavir, nelfinavir, ritonavir, fluvoxamine and saquinavir 6. Use of any of the following cytochrome P450 3A4 inducers in the 14 days preceding enrolment including but not limited to: phenytoin, carbamazepine, barbiturates, rifampin, St. John’s Wort, and glucocorticoids 7. Administration of a depot antipsychotic injection within one dosing interval (for the depot) before randomisation 8. Substance or alcohol dependence at enrolment (except dependence in full remission, and except for caffeine or nicotine dependence), as defined by DSM-IV-R criteria 9. Opiates, amphetamine, barbiturate, cocaine, cannabis, or hallucinogen abuse by DSM-IV-R criteria within 4 weeks prior to enrolment 10. Medical conditions that would affect absorption, distribution, metabolism, or excretion of study treatment 11. Unstable or inadequately treated medical illness (e.g. congestive heart failure, angina pectoris, hypertension) as judged by the investigator 12. Involvement in the planning and conduct of the study 13. Previous enrolment or randomisation of treatment in the present study. 14. Participation in another drug trial within 4 weeks prior enrolment into this study or longer in accordance with local requirements 15. A patient with Diabetes Mellitus (DM) fulfilling one of the following criteria: • Unstable DM defined as enrolment glycosylated hemoglobin (HbA1c) >8.5%. • Admitted to hospital for treatment of DM or DM related illness in past 12 weeks. • Not under physician care for DM • Physician responsible for patient’s DM care has not indicated that patient’s DM is controlled. • Physician responsible for patient’s DM care has not approved patient’s participation in the study • Has not been on the same dose of oral hypoglycaemic drug(s) and/or diet for the 4 weeks prior to randomisation. For thiazolidinediones (glitazones) this period should not be less than 8 Weeks. • Taking insulin whose daily dose on one occasion in the past 4 weeks has been more than 10% above or below their mean dose in the preceding 4 weeks Note: If a diabetic patient meets one of these criteria, the patient is to be excluded even if the treating physician believes that the patient is stable and can participate in the study. 16. An absolute neutrophil count (ANC) of ? 1.5 x 109 per liter 17. Respiratory distress index during the 1st polysomnography > 10 18. Periodic leg movement / arousal index during the 1st polysomnography > 10
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To observe the effects of quetiapine XR (150 - 300 mg daily, given in a single dose at nighttime) on polysomnographically recorded sleep in inpatients suffering from major depression, as compared with mirtazapine (30 – 45 mg). Primary endpoint: Change in polysomnographically measured sleep effiency.;Secondary Objective: (1) To observe the effects of quetiapine XR 150 - 300 mg daily on subjective sleep parameters in these patients, as compared with mirtazapine 30 – 45 mg (2) To observe the antidepressant effect of quetiapine XR 150 - 300 mg daily, as compared with mirtazapine 30 - 45 mg (3) To evaluate the safety and tolerability of quetiapine XR 150 – 300 mg daily in these patients, as compared with mirtazapine 30 – 45 mg (4) To observe the effects of quetiapine XR 150 – 300 mg daily on neuropsychological parameters in these patients, as compared with mirtazapine 30 – 45 mg. ;Primary end point(s): Primary endpoint: Change in polysomnographically measured sleep effiency | — |
Countries
Germany
Outcome results
None listed